En español

Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT)

This 2 stage study will investigate the effectiveness and safety of a combination pharmacotherapy for methamphetamine use disorder.  Stage 1 will include 20 participants with moderate or severe stimulant use disorder who will receive a monthly injection of extended-release depot naltrexone plus once-daily bupropion extended-release tablets for 8 weeks.  If Stage 1 data documents success in at least 3 “responder” study participants, Stage 2 will follow utilizing the same protocol as in Stage 1, to enroll an additional group of 29 participants.

CTN Protocol ID: 
ClinicalTrials.gov ID: 
Principal Investigator(s)
Walter Ling, M.D.
Integrated Substance Abuse Programs
University of California, Los Angeles
11075 Santa Monica Boulevard
Suite 200
Los Angeles, CA 90025

Get this Publication

    Blending Initiative

    blending logo

    Formed with SAMHSA to reduce the gap between research results and treatment.